Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Giuseppina Ricciuti"'
Autor:
E. Pennese, S. Luciani, F. Restuccia, Giuseppina Ricciuti, M. Di Nicola, Francesco Angrilli, C. Cantò
Publikováno v:
Hematological Oncology. 39
Autor:
M. Di Nicola, S. Luciani, Giuseppina Ricciuti, E. Pennese, Francesco Angrilli, C. Cantò, F. Restuccia
Publikováno v:
Annals of Oncology. 32:S777-S778
Autor:
Claudio Cerchione, Nicola Cascavilla, Giuseppina Ricciuti, Giovanni Martinelli, Antonietta Falcone
Publikováno v:
Panminerva medica. 62(4)
The treatment of patients with multiple myeloma has changed in the last decades, with an improved median survival of 8-10 years. The current treatment for newly diagnosed multiple myeloma patients eligible for autologous transplantation consists of 4
Autor:
Nicola Cascavilla, Felicina Li Gioi, Giuseppina Ricciuti, Maurizio Musso, Alessandra Crescimanno, Ferdinando Porretto, Gaetano De Santis, Emilio Iannitto, Annalisa Chiarenza, Ugo Consoli, Attilio Guarini, Maria Cristina Pirosa, Antonino Greco, Giuseppe Tarantini, Marilena Salerno, Saverio Mantuano, Carla Minoia, Donato Mannina, Francesco Di Raimondo, Alessandra Romano, Potito Rosario Scalzulli, Enzo Pavone, Renato Scalone, Anastasia Laura Caruso, Vincenza Bonanno
Publikováno v:
European journal of haematologyREFERENCES. 104(6)
Objective and methods In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patients treated with BvB in second r
Autor:
Elena Ranucci, I.A.L. Zecca, Massimo Federico, Stefania Luciani, Giuseppina Ricciuti, Erica Finolezzi, Marta Di Nicola, Francesco Angrilli
Publikováno v:
Hematological oncology. 36(1)
The incidence of non-Hodgkin lymphoma in patients 80 years of age or older is 50 times higher than in 20- to 24-year-olds. Very elderly patients are often not treated with standard immunochemotherapy because of poor performance status, comorbidities,
Autor:
Vito Franco, Alessandro Pulsoni, Luigi Marcheselli, Giuseppina Ricciuti, Emilio Iannitto, Stefano Luminari, Alberto Fragasso, Francesco Merli, Elisa Montechiarello, Massimo Federico, Claudio Tripodo, Marina Cesaretti, Marco Paulli, Caterina Stelitano, Salvatrice Mancuso, Angelo Michele Carella
Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e3db6cc0d2622384a324d1609ffc7f3
https://hdl.handle.net/11380/1065868
https://hdl.handle.net/11380/1065868
Autor:
Stefano Luminari, Marina Cesaretti, Luca Arcaini, Gianluca Gaidano, Giuseppina Ricciuti, Giuseppina Cabras, Alessandra Tedeschi, Inês B Pereira, Simone Ferrero, Athina Lymboussaki, Michele Merli, Francesca Re, Maria Goldaniga, Rosanna Ciancia, Emanuele Cencini, Massimo Federico, Paola Picardi, Vittoria Tarantino, Donato Mannina, Marco Frigeni, Marcia Torresan Delamain, Federica Cavallo, Sara Rattotti, Angela Ferrari
Publikováno v:
Blood. 126:2686-2686
Background: Indolent non follicular B-Cell Lymphomas (INFL) are a heterogeneous group of lymphomas and include small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphomas (LPL) and marginal zone lymphomas of splenic (SMZL), nodal (NMZL) and extrano
Autor:
Giuseppe Fioritoni, Giuseppina Ricciuti, Paolo Bartolomeo, Antonella Sau, Gaetano La Barba, Simona Sestili, Stefano Pulini
Publikováno v:
Blood. 122:4875-4875
Paroxysmal nocturnal hemoglobinuria (PNH) derives from a non malignant clonal expansion of hematopoietic stem cells (HSCs) harbouring somatic mutations of the X-linked PIG-A gene, leading to the complete or partial loss of glycosylphosphatidylinosito